455 related articles for article (PubMed ID: 11703838)
1. Drug resistance in Indian visceral leishmaniasis.
Sundar S
Trop Med Int Health; 2001 Nov; 6(11):849-54. PubMed ID: 11703838
[TBL] [Abstract][Full Text] [Related]
2. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
3. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.
Singh N; Chatterjee M; Sundar S
Parasit Vectors; 2014 Dec; 7():596. PubMed ID: 25515494
[TBL] [Abstract][Full Text] [Related]
4. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches.
Murray HW
Int J Infect Dis; 2000; 4(3):158-77. PubMed ID: 11179920
[TBL] [Abstract][Full Text] [Related]
5. The treatment of visceral leishmaniasis: safety and efficacy.
Jha RK; Sah AK; Shah DK; Sah P
JNMA J Nepal Med Assoc; 2013; 52(192):645-51. PubMed ID: 25327244
[TBL] [Abstract][Full Text] [Related]
6. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
Dube A; Singh N; Sundar S; Singh N
Parasitol Res; 2005 Jun; 96(4):216-23. PubMed ID: 15868188
[TBL] [Abstract][Full Text] [Related]
7. Leishmaniasis: an update of current pharmacotherapy.
Sundar S; Chakravarty J
Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
[TBL] [Abstract][Full Text] [Related]
8. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
[TBL] [Abstract][Full Text] [Related]
9. Treatment of visceral leishmaniasis.
Sundar S
Med Microbiol Immunol; 2001 Nov; 190(1-2):89-92. PubMed ID: 11770119
[TBL] [Abstract][Full Text] [Related]
10. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis.
Murray HW
Expert Rev Anti Infect Ther; 2004 Apr; 2(2):279-92. PubMed ID: 15482193
[TBL] [Abstract][Full Text] [Related]
11. Challenges and new discoveries in the treatment of leishmaniasis.
Singh S; Sivakumar R
J Infect Chemother; 2004 Dec; 10(6):307-15. PubMed ID: 15614453
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapeutics of visceral leishmaniasis: present and future developments.
Sundar S; Singh A
Parasitology; 2018 Apr; 145(4):481-489. PubMed ID: 29215329
[TBL] [Abstract][Full Text] [Related]
13. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India.
Thakur CP; Dedet JP; Narain S; Pratlong F
Trans R Soc Trop Med Hyg; 2001; 95(2):187-9. PubMed ID: 11355558
[TBL] [Abstract][Full Text] [Related]
14. Management of visceral leishmaniasis: Indian perspective.
Agrawal S; Rai M; Sundar S
J Postgrad Med; 2005; 51 Suppl 1():S53-7. PubMed ID: 16519257
[TBL] [Abstract][Full Text] [Related]
15. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
16. Drug unresponsiveness & combination therapy for kala-azar.
Jha TK
Indian J Med Res; 2006 Mar; 123(3):389-98. PubMed ID: 16778318
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of visceral leishmaniasis in children].
Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
[TBL] [Abstract][Full Text] [Related]
18. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
Murray HW
Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
[No Abstract] [Full Text] [Related]
19. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex.
Sundar S; Goyal AK; More DK; Singh MK; Murray HW
Ann Trop Med Parasitol; 1998 Oct; 92(7):755-64. PubMed ID: 9924533
[TBL] [Abstract][Full Text] [Related]
20. Oral miltefosine treatment in children with visceral leishmaniasis: a brief review.
Palumbo E
Braz J Infect Dis; 2008 Feb; 12(1):2-4. PubMed ID: 18553005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]